Browsing Tag
Eli Lilly and Company
140 posts
Natco Pharma signs licensing deal with Lilly for Covid drug Baricitinib
Natco Pharma has signed a royalty-free, non-exclusive, voluntary licensing agreement with Eli Lilly and Company (Lilly) for manufacturing…
May 18, 2021
Torrent Pharma signs licensing deal with Lilly for Covid drug baricitinib
Torrent Pharmaceuticals (Torrent Pharma) has signed a licensing agreement with Eli Lilly and Company with an objective to…
May 14, 2021
Dr. Reddy’s Laboratories, Lilly sign deal for Covid-19 drug baricitinib
Dr. Reddy’s Laboratories said that it has forged a royalty-free, non-exclusive voluntary licensing agreement with US pharma giant…
May 12, 2021
Sun Pharma signs licensing deal with Lilly for Covid-19 drug baricitinib
Sun Pharmaceutical Industries (Sun Pharma) said that it has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli…
May 10, 2021
Lupin strikes deal with Lilly for Covid-19 drug Baricitinib in India
Lupin Limited said that it has signed a royalty-free, limited, non-exclusive voluntary licensing agreement with Eli Lilly and…
May 10, 2021
Natco Pharma gets CDSCO nod for use of Baricitinib in Covid patients
Natco Pharma has secured emergency use approval for Baricitinib from India’s Central Drugs Standard Control Organization (CDSCO) for…
May 3, 2021
Eli Lilly completes $1.04bn acquisition of Prevail Therapeutics to expand gene therapy program
Eli Lilly and Company has officially finalized its acquisition of Prevail Therapeutics in a deal valued at up…
January 23, 2021
Lilly begins real-world Covid-19 study of bamlanivimab in New Mexico to assess outcomes in high-risk patients
Eli Lilly begins a real-world Covid-19 study of bamlanivimab in New Mexico. Find out how mobile clinics aim to reduce hospitalizations in high-risk patients.
December 19, 2020
Eli Lilly to acquire Prevail Therapeutics for $1.04bn, expanding gene therapy pipeline
Eli Lilly and Company has signed a deal worth up to $1.04 billion to acquire Prevail Therapeutics, a…
December 16, 2020
Lilly partners with UnitedHealth Group for pragmatic study of bamlanivimab in high-risk COVID-19 patients
Eli Lilly and Company (Lilly) has formed a strategic collaboration with UnitedHealth Group to conduct a pragmatic clinical…
December 6, 2020